BNP/CALL/NOVO-NORDISK B/1100/0.1/20.12.24 | Market Closed - Börse Stuttgart 04:02:29 2024-07-05 am EDT | ||
| 0.7 EUR | +4.48% |
|
| Current month | -21.35% | ||
| 1 month | +12.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.7 | +4.48% |
| 24-07-04 | 0.67 | -6.94% |
| 24-07-03 | 0.72 | -4.00% |
| 24-07-02 | 0.75 | -17.58% |
| 24-07-01 | 0.91 | +2.25% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 04:02 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC6MUG |
| ISIN | DE000PC6MUG5 |
| Date issued | 2024-03-14 |
| Strike | 1,100 kr |
| Maturity | 2024-12-20 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.95 € |
|---|---|
| Lowest since issue | 0.39 € |
| Spread | 0.02 € |
| Spread % | 2.70% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
